BioCentury | Jul 6, 2018
Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic...
BC Week In Review | Sep 1, 2017
Clinical News

Eliquis lowers stroke, major bleeding in older non-valvular AF patients

Bristol-Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) said a real-world analysis of U.S. patients ages >65 with non-valvular atrial fibrillation (AF) showed that Eliquis apixaban (BMS-562247-01) significantly reduced the risk of stroke and systemic...
BC Extra | Aug 30, 2017
Clinical News

Eliquis lowers stroke, major bleeding in older NVAF patients

Bristol-Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) said a real-world analysis of patients ages 65 and older with non-valvular atrial fibrillation (NVAF) showed that Eliquis apixaban significantly reduced the risk of stroke and systemic...
BC Innovations | Jun 20, 2017
Distillery Techniques

Drug properties

TECHNOLOGY: Pharmacokinetics / pharmacodynamics; toxicology An in vivo click chemistry reaction could help clear drugs from the circulation in the event of toxicity. The approach involves synthesizing an azide-containing analog of the therapeutic, and administering...
BC Innovations | Jun 15, 2017
Tools & Techniques

Clearing chemistry

A new study has discovered an in vivo use of click chemistry that can rapidly clear drugs from circulation in case of emergency. Although it raises the possibility of a universal safety switch, its adoption...
BC Extra | Jun 14, 2017
Financial News

GenMark raises $75M in upsized follow-on

Molecular diagnostics company GenMark Diagnostics Inc. (NASDAQ:GNMK) raised $75 million through the sale of 6.4 million shares at $11.75 in an upsized follow-on underwritten by JPMorgan, BofA Merrill Lynch, William Blair, Cowen and Raymond James....
BC Week In Review | Nov 30, 2016
Clinical News

Pradaxa: Completed Ph III enrollment

Boehringer completed enrollment of 2,727 patients in the open-label, international Phase III RE-DUAL PCI trial comparing 110 and 150 mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor vs. triple antithrombotic therapy comprising warfarin,...
BC Week In Review | Nov 18, 2016
Clinical News

Xarelto: Ph IIIb PIONEER AF-PCI data

The open-label, international Phase IIIb PIONEER AF-PCI trial in 2,124 patients with non-valvular AF who received background antiplatelet therapy following PCI with stenting showed that once-daily15 mg oral Xarelto plus single antiplatelet therapy (clopidogrel or...
BC Innovations | Sep 29, 2016
Product R&D

Safety Factor

Although the advent of Factor Xa inhibitors improved quality of life for many thrombosis patients, the compounds' bleeding risk prevents use in patient populations with certain co-morbidities, and has prompted a handful of companies to...
BC Week In Review | Sep 12, 2016
Clinical News

Savaysa: Phase IIIb data

Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan   Product: Savaysa ( Lixiana - EU) edoxaban (DU-176b)   Business: Cardiovascular   Molecular target: Factor Xa   Description: Oral Factor Xa inhibitor   Indication: Prevent stroke and systemic embolism...
Items per page:
1 - 10 of 292